Estradiol and Progesterone for Appetite Regulation

(E2 & P4 in EB Trial)

This trial explores how the hormones estradiol and progesterone might affect appetite and energy balance. Participants will receive either estradiol, progesterone, a combination of both, or a placebo. They will engage in lab sessions involving exercise and rest to monitor changes in appetite and energy use. The trial seeks healthy, young, non-smoking men without metabolic diseases such as diabetes or obesity. As an unphased trial, it offers participants the chance to contribute to groundbreaking research on hormone effects.

If you are currently taking anticoagulants, antidiabetic medications, cyclosporine, antihypertensives, or certain other medications like rifampin or St. John's Wort, you cannot participate in this trial. The protocol does not specify if you need to stop other medications, but these specific ones are not allowed.

Past studies have found estradiol to be well-tolerated for treating menopause symptoms and low estrogen levels. Trials with postmenopausal women and hair loss treatments reported side effects as rare and mild. However, safety information warns that estradiol might increase cancer risk or affect fertility, so caution is advised.

Research shows that progesterone is generally safe, particularly regarding risks like blood clots. Some individuals might experience minor side effects, such as changes in weight or appetite, but these are usually insignificant.

When used together, estradiol and progesterone have not shown an increased risk compared to using them separately. However, reports indicate increased risks, such as blood clots and strokes, with long-term use of estrogen and progestin therapies.

Most treatments for appetite regulation focus on behavioral changes or medications that suppress appetite through the brain's hunger signals. Unlike these options, estradiol and progesterone are hormones that may help regulate appetite by affecting the body's energy balance and metabolism directly. Researchers are excited about these treatments because they offer a novel way to potentially influence appetite through hormonal pathways, which might lead to more effective and quicker results in managing appetite compared to traditional methods. The combination of estradiol and progesterone is particularly intriguing as it could synergistically enhance this regulatory effect, providing a more comprehensive approach to appetite management.

This trial will compare the effects of estradiol, progesterone, and their combination on appetite regulation. Studies have shown that estradiol, a form of estrogen, plays a key role in controlling food intake and energy use. Research indicates that estrogen directly affects the brain's area responsible for appetite, particularly the hypothalamus, which regulates hunger. Evidence suggests that estrogen produced in the brain can also help reduce body weight. Progesterone treatment might lower food intake and help manage weight, but some studies show it could also increase appetite and body weight. A combination of estradiol and progesterone has been linked to significant weight loss in postmenopausal women. In this trial, participants will receive either estradiol, progesterone, their combination, or a placebo in different arms to evaluate their effects on appetite and energy use.²³⁴⁶⁷